Echo Therapeutics, Inc. (NASDAQ: ECTE), a medical device company focused on skin permeation, continuous glucose monitoring, and associated technologies, announced today that it has re-established its operational and strategic partnership with Medical Technologies Innovation Asia (MTIA), Ltd., Hong Kong, and has initiated the technology transfer process. The partnership is designed to enable close cooperation between the two companies in order to address China’s growing demand for both glucose monitoring and transdermal drug delivery solutions.
The partnership agreement includes a licensing and technology transfer under which MTIA will manufacture Echo’s proprietary skin permeation and analyte measurement technology.
Help employers find you! Check out all the jobs and post your resume.
